The DOI matches its Crossref record.
Efficacy, Safety, and Tolerability of Extended‐Release Once‐Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients
Abstract
OBJECTIVES: To evaluate the efficacy, safety, and tolerability of a new, once‐daily extended‐release (ER) formulation of tolterodine in treating overactive bladder in older (≥65) and younger (<65) patients. DESIGN: A 12‐week double‐blind, placebo‐controlled clinical trial. SETTING: An international study conducted at 167 medical centers. PARTICIPANTS: One thousand fifteen patients (43.1% aged ≥65) with urge incontinence and urinary frequency. INTERVENTION: Patients were randomized to treatment with tolterodine ER 4 mg once daily (qd) (n = 507) or placebo (n = 508) for 12 weeks. MEASUREMENTS: Efficacy, measured with micturition charts (incontinence episodes, micturitions, volume voided per micturition) and subjective patient assessments, safety, and tolerability endpoints were evaluated, relative to placebo, according to two age cohorts: younger than 65 and 65 and older. RESULTS: Mean age in the older and younger patient cohorts was 74 (range 65–93) and 51 (range 20–64), respectively. Compared with placebo, significant improvements in micturition chart variables with tolterodine ER showed no age‐related differences. Irrespective of age, significantly more tolterodine ER recipients than placebo recipients reported an improvement in urgency symptoms. After 12 weeks of treatment with tolterodine ER, a fivefold increase in the percentage of patients able to finish tasks before voiding in response to urgency was noted in both age groups (<65: from 6.5–32.8%, ≥65: from 5.1–26.2%). Tolterodine ER recipients, irrespective of age, also had significant improvements in their bladder condition than did placebo recipients. Overall, a greater percentage of patients, irrespective of age, perceived any benefit with tolterodine ER than with placebo ( P < .001). Dry mouth (of any severity) was the most common adverse event in both the tolterodine ER and placebo treatment arms, irrespective of age (<65: ER 22.7%, placebo 8.1%; ≥65: ER 24.3%, placebo 7.2%). Few patients (<2%) experienced severe dry mouth. No central nervous system, visual, cardiac (per electrocardiogram), or laboratory safety concerns were noted. Withdrawal rates due to adverse events on tolterodine ER 4 mg qd were comparable in the two age cohorts (<65: 5.5%; ≥65: 5.1%; P = .87). CONCLUSIONS: The new, once‐daily ER formulation of tolterodine is efficacious, safe, and well tolerated in the treatment of patients with symptoms of overactive bladder, irrespective of age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.09.079 · Cited by 710
Drug effects on salivary glands: dry mouth
Scully CBE, C. (2003) · Oral Diseases · doi:10.1034/j.1601-0825.2003.03967.x · Cited by 472
Management of Overactive Bladder
Ouslander, J. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032662 · Cited by 411
Muscarinic receptor antagonists for overactive bladder
Abrams, P., & Andersson, K. (2007) · BJU International · doi:10.1111/j.1464-410x.2007.07205.x · Cited by 405
Wolff, A., Joshi, R. K., Ekström, J., Aframian, D., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 364
Metadata
- Authors
- Zinner, N. R., Mattiasson, A., & Stanton, S. L.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2002-05
- Volume
- 50
- Issue
- 5
- Pages
- 799-807
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2006171475
- Cited by
- 166
- References
- 0
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, Safety, and Tolerability of Extended‐Release Once‐Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients. https://app.cochat.ai/papers/10.1046/j.1532-5415.2002.50203.x
- The paper
- Zinner, N. R., Mattiasson, A., & Stanton, S. L. (2002). Efficacy, Safety, and Tolerability of Extended‐Release Once‐Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients. Journal of the American Geriatrics Society. https://doi.org/10.1046/j.1532-5415.2002.50203.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.